News Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Market Closed - Hong Kong S.E. Other stock markets 04:08:15 2024-04-18 am EDT			5-day change	1st Jan Change
9.65 ^HKD	-0.62%		-8.27%	-50.36%

Apr. 08	Junshi Biosciences Gets Nod to Register Toripalimab Injection	MT
Apr. 07	Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Junshi Biosciences Gets Nod to Register Toripalimab Injection	Apr. 08	MT
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07	AQ
Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07	GL
Shanghai Junshi Biosciences Co., Ltd. Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer	Apr. 07	CI
Shanghai Junshi Biosciences Supplemental NDA for Lipid Drug Accepted by NMPA	Apr. 02	MT
Shanghai Junshi Biosciences Co., Ltd. Announces the Acceptance of the Supplemental New Drug Applications for Ongericimab Injection	Apr. 02	CI
Tranche Update on Shanghai Junshi Biosciences Co., Ltd.'s Equity Buyback Plan announced on September 10, 2023.	Apr. 01	CI
Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates	Mar. 29	GL
Shanghai Junshi Biosciences' Loss Narrows in 2023, Misses Estimates	Mar. 28	MT
Junshi Bio's 2023 Loss Widens, Misses Estimates	Feb. 25	MT
Shanghai Junshi Biosciences Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Junshi Biosciences Proposes Share Buyback	Feb. 02	MT
Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority	Feb. 01	GL
Junshi Says NDA for Anti-Cancer Drug Accepted By Singapore's HSA	Feb. 01	MT
Shanghai Junshi Biosciences Co., Ltd. Announces Acceptation of New Drug Application of Toripalimab by Singapore Health Sciences Authority	Feb. 01	CI
Shanghai Junshi Biosciences to Narrow Losses	Jan. 31	MT
Junshi Bio Inks 40 Million Yuan Deal With Shanghai Allink Biotherapeutics	Jan. 31	MT
Shanghai Junshi Biosciences Co., Ltd. Provides Earnings Guidance for the Year Ended December 31, 2023	Jan. 30	CI
Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer	Jan. 17	GL
Shanghai Junshi Biosciences Co., Ltd. Announces Change of Chief Executive Officer	Jan. 12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Shanghai Junshi Biosciences Co., Ltd.

Equities

1877

CNE100003FF7

Summary

Filters